3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Glioblastoma
5
Glioma
3
Brain Neoplasms
3
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Gliosarcoma
2
Sarcoma
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Disease
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
Sirolimus
3
Melphalan
3
Granulocyte Colony-Stimulating Factor
3
Cyclophosphamide
3
Automobiles
3
pembrolizumab
2
fludarabine
2
etoposide phosphate
2
Stem Cell Transplantation
2
Mesna
2
Immunotherapy
2
Gemcitabine
2
Etoposide
2
Carboplatin
2
Busulfan
2
vorasidenib
1
trametinib
1
tozuleristide
1
sonidegib
1
sodium thiosulfate
1
ripretinib
1
ribociclib
1
pegylated granulocyte colony-stimulating factor
1
lutetium Lu 177 dotatate
1
interferon gamma-1b
1
fludarabine phosphate
1
Watchful Waiting
1
Vorinostat
1
Ursodeoxycholic Acid
1
Topotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
Oncolytic Virotherapy
×
CNS
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled